IFFIm receives A+ rating from the UK’s FCDO for the seventh consecutive year
IFFIm receives A+ rating from the UK’s FCDO for the seventh consecutive year
25 March 2026
FCDO
Latest UK Foreign, Commonwealth & Development Office (FCDO) rating reaffirms IFFIm’s position in global health finance.
IFFIm is proud to announce that the UK’s Foreign, Commonwealth & Development Office has awarded the Facility an A+ score for the seventh year in a row, reaffirming IFFIm’s position as one of the most effective, high-performing and innovative financing mechanisms in global health.
The A+ rating – the FCDO’s highest – reflects IFFIm’s longstanding track record of delivering exceptional value for money, strong governance, predictable financing and life-saving impact for Gavi, the Vaccine Alliance. It also recognises the enduring trust of the UK and all IFFIm donors who rely on the Facility to help drive global immunisation outcomes at scale.
Why IFFIm continues to earn top marks
At the heart of IFFIm’s effectiveness is its ability to provide flexible, timely and strategic financing, enabling Gavi to invest when funds will have the greatest impact. FCDO highlighted several strengths that continue to set IFFIm apart:
- Flexibility to match Gavi’s needs: IFFIm allows Gavi to frontload resources or draw down funds over time, ensuring financing is available exactly when needed, whether to accelerate vaccine introductions, close equity gaps, or respond to shifting programme priorities.
- Long-term, predictable resources for market shaping: Predictability is essential for negotiating better vaccine prices and enabling manufacturers to scale production. IFFIm’s steady funding stream strengthens Gavi’s ability to shape vaccine markets, drive down costs and make long-term commitments that open access for the poorest countries.
- Surge funding for emergencies: Disease outbreaks and health crises demand rapid action. IFFIm gives Gavi access to fast, reliable surge financing – an essential capability during emergencies such as Ebola and, more recently, the COVID-19 pandemic.
- A cost-effective model for donors: IFFIm allows donors to make longterm pledges while delivering immediate impact. By transforming future commitments into up-front resources, IFFIm maximises the lifesaving returns on every contribution.
The A+ rating recognises the enduring trust of the UK and all IFFIm donors who rely on the Facility to help drive global immunisation outcomes at scale.
A recognition of partnership and performance
Across all evaluation periods, the common thread has been IFFIm’s ability to deliver at speed, with stability and strategic value. These are qualities that are increasingly vital as global health challenges become more complex.
Receiving an A+ for the seventh consecutive year underscores IFFIm’s effectiveness not only as a financing tool, but also as a trusted partner to Gavi and donor governments.
Receiving an A+ for the seventh consecutive year underscores IFFIm’s effectiveness not only as a financing tool, but also as a trusted partner to Gavi and donor governments. It reflects the Facility’s commitment to strong stewardship of donor resources, rigorous governance and sustained impact for children and communities around the world.
As IFFIm looks ahead to its 20th anniversary in 2026 – and continues its strategic review – this recognition from the FCDO reinforces the importance of innovative finance in ensuring global immunisation systems remain resilient, equitable, and ready for the future.
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.